Treatment-resistant depression in adolescents: Review and updates on clinical management

Depression and Anxiety

Volumn 28, Issue 11, 2011, Pages 946-954

  Maalouf, Fadi T ^a,b   Atwi, Mia ^a   Brent, David A ^b  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

adolescent; antidepressant; depression; psychotherapy; treatment; treatment resistant

Indexed keywords

AMFEBUTAMONE; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; LIOTHYRONINE; LITHIUM; MIRTAZAPINE; PAROXETINE; QUETIAPINE; VENLAFAXINE;

ABUSE; ACNE; ADOLESCENT; AUTOMUTILATION; COMORBIDITY; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; ELECTROCONVULSIVE THERAPY; ENVIRONMENTAL FACTOR; FAMILY CONFLICT; HOPELESSNESS; HUMAN; MATERNAL DISEASE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; SUICIDAL IDEATION; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT INDICATION; TREATMENT OUTCOME; VAGUS NERVE STIMULATION; WEIGHT GAIN;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DISEASE MANAGEMENT; HUMANS; PREVALENCE; PSYCHOTHERAPY; RISK FACTORS;

EID: 81255179223     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.20884     Document Type: Review

References (81)

1. Birmaher B, Brent D, Bernet W, et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 2007; 46: 1503-1526.
2. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. J Am Med Assoc 2007; 297: 1683-1696.
3. Sackeim HA,. The definition and meaning of treatment-resistant depression. J Clin Psychiatry 2001; 62: 10-17.
4. Brent DA, Birmaher B,. Treatment-resistant depression in adolescents: recognition and management. Child Adolesc Psychiatr Clin N Am 2006; 15: 1015-1034. (Pubitemid 44307685)
5. March J, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: treatment for adolescents with depression study (TADS) randomized controlled trial. J Am Med Assoc 2004; 292: 807-820. (Pubitemid 39079667)
6. March J, Silva S, Curry J, et al. The treatment for adolescents with depression study (TADS): outcomes over 1 year of naturalistic follow-up. Am J Psychiatry 2009; 166: 1141-1149.
7. Kennard BD, Silva SG, Tonev S, et al. Remission and recovery in the treatment for adolescents with depression study (TADS): acute and long-term outcomes. J Am Acad Child Adolesc Psychiatry 2009; 48: 186-195.
8. Emslie GJ, Mayes T, Porta G, et al. Treatment of resistant depression in adolescents (TORDIA): week 24 outcomes. Am J Psychiatry 2010; 167: 782-791.
9. Curry J, Rohde P, Simons A, et al. Predictors and moderators of acute outcome in the treatment for adolescents with depression study (TADS). J Am Acad Child Adolesc Psychiatry 2006; 45: 1427-1439. (Pubitemid 44900916)
10. Wilkinson P, Dubicka B, Kelvin R, Roberts C, Goodyer I,. Treated depression in adolescents: predictors of outcome at 28 weeks. Br J Psychiatry 2009; 194: 334-341.
11. Lewinsohn PM, Rohde P, Seeley JR,. Major depressive disorder in older adolescents: prevalence, risk factors, and clinical implications. Clin Psychol Rev 1998; 18: 765-794. (Pubitemid 28512549)
12. Lewinsohn PM, Pettit JW, Joiner Jr TE, Seeley JR,. The symptomatic expression of major depressive disorder in adolescents and young adults. J Abnorm Psychol 2003; 112: 244-252. (Pubitemid 36583179)
13. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Carmody T, Mayes TL,. Fluoxetine in child and adolescent depression: acute and maintenance treatment. Depress Anxiety 1998; 7: 32-39. (Pubitemid 28248517)
14. Kratochvil CJ, May DE, Silva SG, et al. Treatment response in depressed adolescents with and without co-morbid attention-deficit/hyperactivity disorder in the treatment for adolescents with depression study. J Child Adolesc Psychopharmacol 2009; 19: 519-527.
15. Brent DA, Kolko DJ, Birmaher B, et al. Predictors of treatment efficacy in a clinical trial of three psychosocial treatments for adolescent depression. J Am Acad Child Adolesc Psychiatry 1998; 37: 906-914. (Pubitemid 28406737)
16. Clarke G, Hops H, Lewinsohn P, Andrews J, Seeley J, Williams J,. Cognitive-behavioral group treatment of adolescent depression: prediction of outcome. Behav Ther 1992; 23: 341-354.
17. Asarnow JR, Emslie G, Clarke G, et al. Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response. J Am Acad Child Adolesc Psychiatry 2009; 48: 330-339.
18. Goldstein BI, Shamseddeen W, Spirito A, et al. Substance use and the treatment of resistant depression in adolescents. J Am Acad Child Adolesc Psychiatry 2009.
19. Lewinsohn PM, Seeley JR, Hibbard J, Rohde P, Sack WH,. Cross-sectional and prospective relationships between physical morbidity and depression in older adolescents. J Am Acad Child Adolesc Psychiatry 1996; 35: 1120-1129. (Pubitemid 26282592)
20. Kovacs M, Mukerji P, Iyengar S, Drash A,. Psychiatric disorder and metabolic control among youths with IDDM. A longitudinal study. Diabetes Care 1996; 19: 318-323. (Pubitemid 26115453)
21. Schosser A, Kasper S,. The role of pharmacogenetics in the treatment of depression and anxiety disorders. Int Clin Psychopharmacol 2009; 24: 277-288.
22. Lin E, Chen PS,. Pharmacogenomics with antidepressants in the STAR*D study. Pharmacogenomics 2008; 9: 935-946.
23. Sakolsky DJ, Perel JM, Emslie GJ, et al. Antidepressant exposure as a predictor of clinical outcomes in the treatment of resistant depression in adolescents (TORDIA) study. J Clin Psychopharmacol 2011; 31: 92-97.
24. Woldu H, Porta G, Goldstein T, et al. Pharmacokinetically and clinician-determined adherence to an antidepressant regimen and clinical outcome in the treatment of SSRI-resistant depression in adolescents (TORDIA) clinical trial. In press.
25. Kronenberg S, Apter A, Brent D, et al. Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders. J Child Adolesc Psychopharmacol 2007; 17: 741-750. (Pubitemid 351158594)
26. Brent D, Melhem N, Ferrell R, et al. Association of FKBP5 polymorphisms with suicidal events in the treatment of resistant depression in adolescents (TORDIA) study. Am J Psychiatry 2010; 167: 190-197.
27. Wagner BM,. Family risk factors for child and adolescent suicidal behavior. Psychol Bull 1997; 121: 246-298. (Pubitemid 127705293)
28. Feeny NC, Silva SG, Reinecke MA, et al. An exploratory analysis of the impact of family functioning on treatment for depression in adolescents. J Clin Child Adolesc Psychol 2009; 38: 814-825.
29. Brent DA, Emslie GJ, Clarke GN, et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Am J Psychiatry 2009; 166: 418-426.
30. Swartz HA, Frank E, Zuckoff A, et al. Brief interpersonal psychotherapy for depressed mothers whose children are receiving psychiatric treatment. Am J Psychiatry 2008; 165: 1155-1162.
31. Weissman MM, Pilowsky DJ, Wickramaratne PJ, et al. Remissions in maternal depression and child psychopathology: a STAR*D-child report. J Am Med Assoc 2006; 295: 1389-1398.
32. Lewis CC, Simons AD, Nguyen LJ, et al. Impact of childhood trauma on treatment outcome in the treatment for adolescents with depression study (TADS). J Am Acad Child Adolesc Psychiatry 2010; 49: 132-140.
33. Geller B, Fox LW, Clark KA,. Rate and predictors of prepubertal bipolarity during follow-up of 6- to 12-year-old depressed children. J Am Acad Child Adolesc Psychiatry 1994; 33: 461-468. (Pubitemid 24133064)
34. Shamseddeen W, Asarnow JR, Clarke G, et al. Impact of physical and sexual abuse on treatment response in the treatment of resistant depression in adolescents study (TORDIA). J Am Acad Child Adolesc Psychiatry 2011, in press.
35. Berk M, Dodd S,. Antidepressants and adolescents: the bipolar confound? Hum Psychopharmacol 2005; 20: 1-2. (Pubitemid 40227639)
36. Strober M, Carlson G,. Bipolar illness in adolescents with major depression: clinical, genetic, and psychopharmacologic predictors in a three- to four-year prospective follow-up investigation. Arch Gen Psychiatry 1982; 39: 549-555. (Pubitemid 12125546)
37. Wilens TE, Wyatt D, Spencer TJ,. Disentangling disinhibition. J Am Acad Child Adolesc Psychiatry 1998; 37: 1225-1227. (Pubitemid 28487828)
38. Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D,. Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med 2004; 158: 773-780. (Pubitemid 39025076)
39. Kennard BD, Clarke GN, Weersing VR, et al. Effective components of TORDIA cognitive-behavioral therapy for adolescent depression: preliminary findings. J Consult Clin Psychol 2009; 77: 1033-1041.
40. McCarty CA, Weisz JR,. Effects of psychotherapy for depression in children and adolescents: what we can (and can't) learn from meta-analysis and component profiling. J Am Acad Child Adolesc Psychiatry 2007; 46: 879-886. (Pubitemid 46975924)
41. Brent D, Emslie G, Clarke G, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. J Am Med Assoc 2008; 299: 901-913. (Pubitemid 351397065)
42. McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 2006; 163: 1531-1541; quiz 1666. (Pubitemid 44465752)
43. Nolen WA, van de Putte JJ, Dijken WA, et al. Treatment strategy in depression. II. MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. Acta Psychiatr Scand 1988; 78: 676-683. (Pubitemid 19027334)
44. Sallee FR, Vrindavanam NS, Deas-Nesmith D, Carson SW, Sethuraman G,. Pulse intravenous clomipramine for depressed adolescents: double-blind, controlled trial. Am J Psychiatry 1997; 154: 668-673. (Pubitemid 27197601)
45. Kennard B, Silva S, Vitiello B, et al. Remission and residual symptoms after short-term treatment in the treatment of adolescents with depression study (TADS). J Am Acad Child Adolesc Psychiatry 2006; 45: 1404-1411. (Pubitemid 44900913)
46. Vitiello B, Rohde P, Silva S, et al. Functioning and quality of life in the treatment for adolescents with depression study (TADS). J Am Acad Child Adolesc Psychiatry 2006; 45: 1419-1426. (Pubitemid 44900915)
47. Dubicka B, Elvins R, Roberts C, Chick G, Wilkinson P, Goodyer IM,. Combined treatment with cognitive-behavioural therapy in adolescent depression: meta-analysis. Br J Psychiatry 2010; 197: 433-440.
48. Goodyer I, Dubicka B, Wilkinson P, et al. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. Br Med J 2007; 335: 142.
49. Bauer M, Dopfmer S,. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 1999; 19: 427-434. (Pubitemid 29451507)
50. Fava M, Alpert J, Nierenberg A, et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol 2002; 22: 379-387. (Pubitemid 34810327)
51. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006; 163: 1519-1530; quiz 1665. (Pubitemid 44465751)
52. Ryan ND, Meyer V, Dachille S, Mazzie D, Puig-Antich J,. Lithium antidepressant augmentation in TCA-refractory depression in adolescents. J Am Acad Child Adolesc Psychiatry 1988; 27: 371-376.
53. Strober M, Freeman R, Rigali J, Schmidt S, Diamond R,. The pharmacotherapy of depressive illness in adolescence: II. Effects of lithium augmentation in nonresponders to imipramine. J Am Acad Child Adolesc Psychiatry 1992; 31: 16-20.
54. Rush AJ, Warden D, Wisniewski SR, et al. STAR*D: revising conventional wisdom. CNS Drugs 2009; 23: 627-647.
55. Nelson JC, Papakostas GI,. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166: 980-991.
56. Emslie GJ, Mayes T, Porta G, et al. Treatment of resistant depression in adolescents (TORDIA): week 24 outcomes. Am J Psychiatry 2010.
57. Pathak S, Johns ES, Kowatch RA,. Adjunctive quetiapine for treatment-resistant adolescent major depressive disorder: a case series. J Child Adolesc Psychopharmacol 2005; 15: 696-702. (Pubitemid 41434374)
58. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK,. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. J Am Med Assoc 2009; 302: 1765-1773.
59. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354: 1243-1252.
60. Daviss WB, Bentivoglio P, Racusin R, Brown KM, Bostic JQ, Wiley L,. Bupropion sustained release in adolescents with comorbid attention-deficit/ hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry 2001; 40: 307-314. (Pubitemid 32179966)
61. Glod CA, Lynch A, Flynn E, Berkowitz C, Baldessarini RJ,. Open trial of bupropion SR in adolescent major depression. J Child Adolesc Psychiatr Nurs 2003; 16: 123-130.
62. Rey JM, Walter G,. Half a century of ECT use in young people. Am J Psychiatry 1997; 154: 595-602. (Pubitemid 27197590)
63. Ishihara K, Sasa M,. Mechanism underlying the therapeutic effects of electroconvulsive therapy (ECT) on depression. Jpn J Pharmacol 1999; 80: 185-189. (Pubitemid 29381085)
64. Ghaziuddin N, Kutcher SP, Knapp P, et al. Practice parameter for use of electroconvulsive therapy with adolescents. J Am Acad Child Adolesc Psychiatry 2004; 43: 1521-1539.
65. Strober M, Rao U, DeAntonio M, et al. Effects of electroconvulsive therapy in adolescents with severe endogenous depression resistant to pharmacotherapy. Biol Psychiatry 1998; 43: 335-338. (Pubitemid 28137625)
66. Nemeroff CB, Mayberg HS, Krahl SE, et al. VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. Neuropsychopharmacology 2006; 31: 1345-1355.
67. Rush AJ, Marangell LB, Sackeim HA, et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005; 58: 347-354. (Pubitemid 41219702)
68. Borckardt JJ, Anderson B, Andrew Kozel F, et al. Acute and long-term VNS effects on pain perception in a case of treatment-resistant depression. Neurocase 2006; 12: 216-220. (Pubitemid 44473406)
69. Avery DH, Holtzheimer III PE, Fawaz W, et al. A controlled study of repetitive transcranial magnetic stimulation in medication-resistant major depression. Biol Psychiatry 2006; 59: 187-194. (Pubitemid 43117509)
70. Bloch Y, Grisaru N, Harel EV, et al. Repetitive transcranial magnetic stimulation in the treatment of depression in adolescents: an open-label study. J ECT 2008; 24: 156-159.
71. Birmaher B, Brent DA, Kolko D, et al. Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder. Arch Gen Psychiatry 2000; 57: 29-36. (Pubitemid 30035656)
72. Diamond GS, Wintersteen MB, Brown GK, et al. Attachment-based family therapy for adolescents with suicidal ideation: a randomized controlled trial. J Am Acad Child Adolesc Psychiatry 2010; 49: 122-131.
73. Roane BM, Taylor DJ,. Adolescent insomnia as a risk factor for early adult depression and substance abuse. Sleep 2008; 31: 1351-1356.
74. Tao R, Emslie GJ, Mayes TL, Nakonezny PA, Kennard BD,. Symptom improvement and residual symptoms during acute antidepressant treatment in pediatric major depressive disorder. J Child Adolesc Psychopharmacol 2010; 20: 423-430.
75. Manber R, Edinger JD, Gress JL, San Pedro-Salcedo MG, Kuo TF, Kalista T,. Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia. Sleep 2008; 31: 489-495. (Pubitemid 351694271)
76. Maalouf FT, Brent D, Clark L, et al. Neurocognitive impairment in adolescent major depressive disorder: state vs. trait illness markers. J Affect Disord 2011.
77. Dunkin JJ, Leuchter AF, Cook IA, Kasl-Godley JE, Abrams M, Rosenberg-Thompson S,. Executive dysfunction predicts nonresponse to fluoxetine in major depression. J Affect Disord 2000; 60: 13-23. (Pubitemid 30625240)
78. Mayberg HS, Brannan SK, Mahurin RK, et al. Cingulate function in depression: a potential predictor of treatment response. Neuroreport 1997; 8: 1057-1061. (Pubitemid 27152174)
79. Vitiello B, Silva SG, Rohde P, et al. Suicidal events in the treatment for adolescents with depression study (TADS). J Clin Psychiatry 2009; 70: 741-747.
80. Wilkinson P, Kelvin R, Roberts C, Dubicka B, Goodyer I,. Clinical and psychosocial predictors of suicide attempts and nonsuicidal self-injury in the adolescent depression antidepressants and psychotherapy trial (ADAPT). Am J Psychiatry 2011; 168: 495-501.
81. Stanley B, Brown G, Brent DA, et al. Cognitive-behavioral therapy for suicide prevention (CBT-SP): treatment model, feasibility, and acceptability. J Am Acad Child Adolesc Psychiatry 2009; 48: 1005-1013.